Authors Posts by Head Editor

Head Editor

5140 POSTS 18 COMMENTS

0 1252

Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment

GlobeNewswire
SILVER SPRING, Md., Nov. 7, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary Nuvilex Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug Designation for its pancreatic cancer treatment. This submission follows similar applications to the United States Food and Drug Administration and the European Medicines Agency in the European Union (EU). Like those in the U.S. (7 years) and the EU (10 years), granting of the Orphan Drug Designation carries with it a significant period of marketing exclusivity. In Australia this period is 5 years.

Nuvilex’s CEO and President, Kenneth L. Waggoner, commented, “The application for the Orphan Drug Designation in Australia is the third such application made to the drug regulatory authorities in major areas of the world. In order for the Orphan Drug Designation to be granted to a particular drug or treatment, the target disease must be considered life-threatening and ‘rare.’ Pancreatic cancer, no matter where it occurs in the world, is undoubtedly life-threatening and, in our opinion, its prevalence in Australia classifies it as a rare disease. It is expected that this application to the TGA will be reviewed relatively quickly, and we may have a decision on it before the end of the year.”

Nuvilex’s pancreatic cancer treatment consists of implanting living cells that have been encapsulated in pin-head sized, cellulose-based, protective “cocoons” through the use of the proprietary Cell-in-a-Box(R) technology, followed by the administration of low doses of the anticancer prodrug ifosfamide. Ifosfamide is a drug that must be converted into its “cancer-killing” form for it to be effective. The cells that are encapsulated are efficient and effective at carrying out this conversion. By placing these encapsulated ifosfamide-activating cells in proximity to the pancreatic cancer, the anticancer effects of the drug are optimized. In addition, as shown in early-phase clinical trials, because low doses of the anticancer drug are used the side effects from it are greatly reduced in severity and the treatment is well tolerated by the patients undergoing this novel treatment.

Mr. Waggoner continued, “As with the applications for the Orphan Drug Designation in the U.S. and the EU, we are extremely grateful to our colleagues at Clinical Network Services (CNS) for their assistance in the preparation of this Australian submission. In particular, the services of Dr. Natalie Thomas in the preparation and submission of this application were invaluable. CNS, one of Australia’s leading Contract Research Organizations, has been contracted by Nuvilex to conduct its Phase 2b pancreatic cancer clinical trial in that country.”

About Nuvilex

Nuvilex (NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex’s treatment for pancreatic cancer involves the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. Nuvilex is also working toward improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, Nuvilex is developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids. Nuvilex is examining ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of such cannabinoids against cancers, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Nuvilex a unique opportunity to develop “green” approaches to fighting deadly cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor

This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include Nuvilex’s ability to continue as a going concern, delays or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex’s intellectual property and Nuvilex’s continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.

More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.

Contact:
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
Cmatschullat@bplifescience.com

0 1458

Form 8-K for VAPORIN, INC.

7-Nov-2014

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Item 1.01 Entry into Material Definitive AgreementOn November 6, 2014, Vaporin, Inc. (“Vaporin”) entered into a binding term sheet
(the “Term Sheet”) related to a proposed merger with Vapor Corp. (“Vapor”)
(“Vapor”, and together with Vaporin, the “Parties”) and Vapor entered into a financing transaction with certain third parties. Vapor will be the surviving company.

As consideration for the merger, the Term Sheet provides that the stockholders of Vaporin will receive the number of shares of Vapor’s common stock such that the former Vaporin stockholders will collectively own 45.0% of the issued and outstanding shares of common stock of the combined company following consummation of the merger, subject to any adjustments to the exchange ratio which would be necessary to permit the respective financial advisers of both the Parties to make the determination that the merger consideration is fair from a financial perspective. The Term Sheet provides that the shares of Vapor’s common stock to be issued in upon consummation of the proposed merger will be registered on a Form S-4 registration statement (the “Registration Statement”) to be filed with the U.S. Securities and Exchange Commission (the “Commission”). The Term Sheet also prohibits both the Parties from entering into discussions or negotiations of any kind (written or oral) with any other entity or person, perform any actions of any kind that are inconsistent in any way with the matters discussed in the Term Sheet, or entertain, solicit, or consider any offers, terms, conditions, or provisions from any other entity or person regarding any transaction involving a sale of all or substantially all of the assets of either Party, as applicable, a merger, consolidation, or recapitalization of Vapor or Vaporin, as applicable, or any similar transaction until March 31, 2015, subject to certain exceptions.

In addition to the proposed merger, the Term Sheet also provides the material terms for a series of financing transactions. The first financing is a bridge loan where Michael Brauser and Barry Honig (the “Investors”) or their affiliates will purchase $1.0 million in senior secured convertible notes and warrants to purchase shares of Vapor’s common stock. The Investors signed a binding Term Sheet on November 6, 2014 agreeing to fund the $1 million within five days. Pursuant to the merger Term Sheet, a second equity financing of $3.5 million is expected to close contingent on the closing of the merger with Vapor. The Term Sheet also contemplates that following the merger, Vapor may receive up to a total of $25.0 million in additional equity investments subject to financial covenants and performance-based metrics still to be negotiated and documented in the final definitive agreements.

The merger Term Sheet further provides that the merger agreement and financings will include certain customary conditions to closing, including that the consummation of the transactions contemplated by the merger agreement to be entered into shall be subject to, among other things, (i) the receipt by each of the Parties of an independent fairness issued by a separate independent investment bank which provides a favorable opinion regarding the financial terms and conditions of the proposed merger; (ii) satisfactory completion of due diligence by each of the Parties; (iii) the Registration Statement being declared effective by the Commission and no stop orders from any regulatory authority being in place; (iv) the receipt of approval by the stockholders of the Parties to the merger and merger agreement; and (v) the receipt by both Parties of all required regulatory approvals, including from The NASDAQ Stock Market.

The foregoing summary of the Term Sheet is not complete and is qualified in its entirety by reference to the full text of the Term Sheet, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and which is incorporated by reference herein.

Additional Information and Where to Find It.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed merger and upon the execution of a definitive merger agreement, Vapor intends to file a Registration Statement on Form S-4 that will include a joint proxy statement of Vapor and Vaporin and a prospectus of Vapor with the Commission. Both Vapor and Vaporin may file other documents with the Commission regarding the proposed transaction. If a definitive merger agreement is executed by the parties, a definitive joint proxy statement will be mailed to the stockholders of Vapor and Vaporin. Investors and security holders are advised to read the joint proxy statement/prospectus when it becomes available, and any other relevant documents filed with the Commission, as well as any amendments or supplements to the documents, because they will contain important information. Investors and security holders may obtain a free copy of the registration statement (when available), including the joint proxy statement/prospectus and other documents containing information about Vapor and Vaporin at the Commission’s website at www.sec.gov. These documents may be accessed and downloaded for free at Vapor’s website at www.vapor-corp.com or by directing a request to Harlan Press, Chief Financial Officer, Vapor Corp., at 3001 Griffin Road, Dania Beach, Florida 33312, telephone (888) 766-5351 or at www.vaporin.com or by directing a request to Jim Martin, Chief Financial Officer, Vaporin, Inc. at 4400 Biscayne Boulevard, Miami, Florida 33137, telephone (305) 576-9298.

Participants in the Solicitation.

This communication is not a solicitation of a proxy from any security holder of Vapor or Vaporin. However, Vapor and Vaporin, and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Vapor’s and Vaporin’s stockholders in respect of the proposed merger. Information regarding the directors and executive officers of Vapor may be found in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the Commission on February 26, 2014, and its Current Report on Form 8-K dated April 25, 2014, as filed with the Commission on April 28, 2014, both of which Reports can be obtained free of charge from Vapor’s website. Information regarding the directors and executive officers of Vaporin may be found in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the Commission on March 27, 2014 and can be obtained free of charge from Vaporin’s website. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Joint Proxy Statement/Prospectus and other relevant materials to be filed with the Commission when they become available.

Forward Looking Statements

The foregoing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to those regarding the proposed merger and proposed financing. Such statements are not historical facts and include expressions about management’s confidence and strategies and management’s expectations about new and existing programs and products, relationships, opportunities, taxation, technology and market conditions. These statements may be identified by such forward-looking terminology as “expect,” “believe,” “view,” “opportunity,” “allow,” “continues,” “reflects,” “typically,” “usually,” “anticipate,” or similar statements or variations of such terms. Such forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from such forward-looking statements. Factors that may cause actual results to differ from those contemplated by such forward-looking statements include, but are not limited to, the following: failure to enter into a definitive merger agreement; failure to enter into a potential financing transaction, reaction to the proposed merger of the Parties’ customers and employees; the diversion of management’s time on issues relating to the merger; the inability to realize expected cost savings and synergies from the merger of Vapor with Vaporin in the amounts or in the timeframe anticipated; the Parties’ operations and their ability to successfully execute their current business strategy changes in the estimate of non-recurring charges; costs or difficulties relating to integration matters might be greater than expected; changes in the stock price of Vapor or Vaporin prior to closing; material adverse changes in Vaporin’s or Vapor’s operations or earnings; the inability to retain the Parties’ customers and employees; or a decline in the economy, as well as the risk factors set forth in the Parties’ Form 10-Ks (and as supplemented by later filings with the Commission). Neither Vapor nor Vaporin assumes any obligation for updating any such forward-looking statement at any time.

 

Item 9.01 Financial Statements and Exhibits(d) Exhibits

10.1 Binding Term Sheet for Proposed Merger and Financing Transactions, dated as of November 6, 2014.

99.1 Press Release, dated November 6, 2014.

 

0 1258

GB Sciences and MJ Freeway Collaborate on Cannabis Patient Care and Commerce App

GlobeNewswire
LAS VEGAS, Nov. 7, 2014 (GLOBE NEWSWIRE) — GrowBLOX Sciences, Inc., “GB Sciences” (GBLX), a company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize our safe and consistent medicinal cannabis, has joined forces with cannabis industry enterprise software leader MJ Freeway to develop a breakthrough app which will enhance the medical cannabis patient experience. The free downloadable software will empower patients to register, make purchases, schedule pickup orders and—where available—request delivery of GB Sciences products.

“This innovative software solution will empower patients to interact with us at any time and from any place using their mobile devices,” said Craig Ellins, CEO of GB Sciences, Inc. “We are very excited to work with MJ Freeway, the leader in the cannabis enterprise software space.”

Integrated with MJ Freeway’s pioneering cannabis software and hardware solution, the app will facilitate the collection of symptom and product information to support GB Sciences’ research and development endeavors.

“We are constantly expanding the capabilities of our platform and solutions,” said MJ Freeway cofounder Amy Poinsett. “With the explosive growth in both the marijuana industry and the mobile web, it is critical that we offer our dispensary and retail customers the ability to communicate with their mobile customers.

“We are excited to be able to integrate our platform with this mobile app in conjunction with GB Sciences, a company with a passionate commitment for elevating product and service standards in this marketplace.”

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., “GB Sciences” (GBLX)—is a biopharmaceutical research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The company is pioneering technology, industry-leading processes, and big data-driven clinical research and development loop ability to bring relief to patients in communities across the country.

To learn more about GB Sciences, Inc., go to www.gbsciences.com.

About MJ Freeway

MJ Freeway makes running a cannabis business easy with seed-to-sale tracking software that manages every plant, gram, and dollar. This industry-leading technology provides patent-pending inventory control and grow management applications for a precise chain of custody, with unlimited remote technical support. Guaranteed to meet any state tracking requirements, MJ Freeway is the solution for marijuana producers, processors, infused product manufacturers, and retailers.

To learn more about MJ Freeway, go to www.mjfreeway.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View photo

.

Contact:
Media and Investor Relations Contact:
Stephen Hart
Hayden IR
hart@haydenir.com
917-658-7878

0 1433

Vapor Corp. Announces Execution of a Term Sheet to Merge with Vaporin, Inc. and Releases Certain Preliminary Third Quarter Financial Results

DANIA BEACH, Fla., — Vapor Corp. (VPCO) (“Vapor” or the “Company“), a U.S.-based vaporizer and electronic cigarette company, announced today, that it has executed a binding term sheet (“Term Sheet“) to enter into a merger with Vaporin, Inc. (VAPO) (“Vaporin“), a company whose primary focus is in vaporizers and eliquids.

The Term Sheet contemplates a proposed merger with Vaporin to be structured as a merger of equals with Vapor as the surviving party in the transaction. As consideration for the merger, the Term Sheet provides that the stockholders of Vaporin would be entitled to receive the number of shares of the Company’s common stock such that the former Vaporin stockholders would collectively own 45.0% of the issued and outstanding shares of common stock of the combined company following consummation of the merger, subject to any adjustments to the exchange ratio which would be necessary to permit the respective financial advisers of both the Company and Vaporin to make the determination that the merger consideration is fair from a financial perspective.

The Term Sheet further contemplates, in connection with the proposed merger, a series of financing transactions.  The first financing is expected to consist of a bridge loan where Michael Brauser and Barry Honig (the “Investors“) or their affiliates will purchase $1.0 million in senior secured convertible notes and warrants to purchase shares of the Company’s common stock.  The Investors are shareholders of Vaporin.  Pursuant to the Term Sheet, a second equity financing of $3.5 million is expected to close contingent on the closing of the merger with Vaporin.  The Term Sheet also contemplates that the Company may receive up to a total of $25.0 million in additional equity investments subject to financial covenants and performance-based metrics still to be negotiated and documented in the final definitive agreements.

The Company believes the potential financings, if consummated, would allow the Company to continue to execute its strategy to attempt to capture an increased share of the rapidly expanding vaporizer market.

By signing the Term Sheet, the parties have agreed to negotiate in good faith and to execute definitive agreements as soon as possible, but in any event prior to December 21, 2014, and to otherwise use best efforts to consummate the transactions contemplated by the Term Sheet on an expedited basis.  The parties are currently in the process of negotiating such definitive agreements, which are subject to approval of each party’s board of directors.  The proposed merger and financings remain subject to receipt of fairness opinions, due diligence, stockholder votes, and other customary closing conditions.

Financial Results

The Company will release its financial results for the third quarter and nine months of 2014 after the market closes on Friday, November 14, 2014. Highlights will include six (6) new retail kiosk locations opened in major U.S. shopping malls, since November 1, 2014, and reported net sales of $2,673,926 and $13,547,792 for the three and nine months ended September 30, 2014, respectively, which represent decreases of 58.3% and 28.5%, respectively compared to the prior year periods.  The decrease in sales is primarily attributable to decreased sales of the Company’s television direct marketing campaign for the Company’s Alternacig® and VaporX® branded campaigns, decreases in sales from our on-line stores, distributor inventory build leveling off in 2014 and continued pipeline load in the e-cigarette category in 2013, and the increasing prevalence of vaporizers, tanks and open system vapor products that are marginalizing the e-cigarette category. Sales were also negatively impacted by new national competitors’ launches of their own branded products during 2014.  The Company expects to report net losses of $4.8 million and $7.3 million for the three and nine months ended September 30, 2014, respectively, compared to net income of $0.3 million and $0.3 million for the three and nine months ended September 30, 2013, respectively.

About Vapor Corp.  Vapor Corp., a NASDAQ listed company, is a U.S. based vaporizer and electronic cigarette company, whose brands include emagine vapor, Krave®, VaporX®, Hookah Stix®, Alternacig® and Fifty-One®. We also design and develop private label brands for some of our distribution customers. “Electronic cigarettes” or “e-cigarettes,” and “Vaporizers,” are battery-powered products that enable users to inhale nicotine vapor without smoke, tar, ash or carbon monoxide. Vapor’s electronic cigarettes, vaporizers and accessories are available online, through our company owned stores under the emagine vapor brand, through direct response to our television advertisements and through retail locations throughout the United States. For more information on Vapor Corp. and its e-cigarette and vaporizer brands, please visit us at www.vapor-corp.com.

Forward Looking Statements

The foregoing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to those regarding the proposed merger and proposed financing.  Such statements are not historical facts and include expressions about management’s confidence and strategies and management’s expectations about new and existing programs and products, relationships, opportunities, taxation, technology and market conditions.  These statements may be identified by such forward-looking terminology as “expect,” “believe,” “view,” “opportunity,” “allow,” “continues,” “reflects,” “typically,” “usually,” “anticipate,” or similar statements or variations of such terms.  Such forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from such forward-looking statements. Factors that may cause actual results to differ from those contemplated by such forward-looking statements include, but are not limited to, the following: failure to enter into a definitive merger agreement; failure to enter into a potential financing transaction, reaction to the proposed merger of Vapor’s customers and employees; the diversion of management’s time on issues relating to the merger; the inability to realize expected cost savings and synergies from the merger of Vapor with Vaporin in the amounts or in the timeframe anticipated; Vapor’s operations and its ability to successfully execute its current business strategy changes in the estimate of non-recurring charges; costs or difficulties relating to integration matters might be greater than expected; changes in the stock price of Vapor or Vaporin prior to closing; material adverse changes in Vaporin’s or Vapor’s operations or earnings; the inability to retain Vapor’s customers and employees; or a decline in the economy, as well as the risk factors set forth in Vapor Form 10-K (and as supplemented by Item 1.A. in Vapor’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014) and the Vaporin Form 10-K. Neither Vapor nor Vaporin assumes any obligation for updating any such forward-looking statement at any time.

Additional Information and Where to Find It

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.  In connection with the proposed merger and upon the execution of a definitive merger agreement, Vapor intends to file a Registration Statement on Form S-4 that will include a joint proxy statement of Vapor and Vaporin and a prospectus of Vapor with the Securities and Exchange Commission (the “Commission“).  Both Vapor and Vaporin may file other documents with the Commission regarding the proposed transaction. If a definitive merger agreement is executed by the parties, a definitive joint proxy statement will be mailed to the stockholders of Vapor and Vaporin. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE COMMISSION, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.  Investors and security holders may obtain a free copy of the registration statement (when available), including the joint proxy statement/prospectus and other documents containing information about Vapor and Vaporin at the Commission’s website at www.sec.gov.  These documents may be accessed and downloaded for free at Vapor’s website at www.vapor-corp.com or by directing a request to Harlan Press, Chief Financial Officer, Vapor Corp., at 3001 Griffin Road, Dania Beach, Florida 33312, telephone (888) 766-5351 or at www.vaporin.com or by directing a request to Jim Martin, Chief Financial Officer, Vaporin, Inc. at 4400 Biscayne Boulevard, Miami, Florida 33137, telephone (305) 576-9298.

Participants in the Solicitation

This communication is not a solicitation of a proxy from any security holder of Vapor or Vaporin.  However, Vapor and Vaporin and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Vapor’s and Vaporin’s stockholders in respect of the proposed merger.  Information regarding the directors and executive officers of Vapor may be found in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the “Registrant Form 10-K“), which was filed with the Commission on February 26, 2014, and its Current Report on Form 8-K dated April 25, 2014 , as filed with the Commission on April 28, 2014, both of which Reports can be obtained free of charge from Vapor’s website.  Information regarding the directors and executive officers of Vaporin may be found in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the “Vaporin Form 10-K“), which was filed with the Commission on March 27, 2014 and can be obtained free of charge from Vaporin’s website.  Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Joint Proxy Statement/Prospectus and other relevant materials to be filed with the Commission when they become available.

 

0 1457

Form 8-K for PRIMCO MANAGEMENT INC.

Unregistered Sale of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities.On October 13, 2014, the registrant issued 227,272,728 shares of common stock to Magna Management, LLC, in partial satisfaction of its obligations under, and the holder’s election to convert a portion of, the Primco Management, Inc. $50,000 Twelve Percent (12%) Convertible Note Dated February 5, 2014, held by Magna Group, LLC.

On October 13, 2014, the registrant issued 200,000,000 shares of common stock to Firehole River Capital, LLC (“FRC”), in partial satisfaction of its obligations under, and the holder’s election to convert a portion of, the US $ 75,000 Replacement Note – Originally Issued November 6, 2012 in the Amount of $275,000
[to Gorilla Pictures], held by FRC.

On October 21, 2014, the registrant issued 128,322,603 shares of common stock to WHC Capital, LLC (“WHC”), in full satisfaction of its remaining obligations under its convertible notes with WHC in the amount of $50,000 on June 27, 2013, in the amount of $100,000 on August 8, 2013, in the amount of $100,000 on September 8, 2013, in the amount of $50,000 on October 22, 2013, in the amount of $50,000 on November 30, 2013, and in the amount $50,000 on December 27, 2013; as well its settlement letter agreement with WHC dated May 12, 2014. The registrant has made the required settlement cash payments of $150,000, and is not obligated to issue any additional shares to WHC under the above-described notes.

On October 21, 2014, the registrant issued 118,779,546 shares of common stock to SFH Capital, LLC (“SFH”), in full satisfaction of its remaining obligations under three Common Stock Subscription Agreements with SFH dated April 7, 2014, April 27, 2014, and May 9, 2014.

On October 23, 2014, the registrant issued 173,860,300 shares of common stock to LG Capital Funding LLC (“LG”), in partial satisfaction of its obligations under, and the holder’s election to convert a portion of, the Primco Management, Inc. 8% Convertible Redeemable Note Due February 20, 2015, dated February 20, 2014, held by LG.

On October 29, 2014, the registrant issued 316,438,400 shares of common stock to LG Capital Funding LLC (“LG”), in full satisfaction of its remaining obligations under, and the holder’s election to convert a portion of, the Primco Management, Inc. 8% Convertible Redeemable Note Due February 20, 2015, dated February 20, 2014, held by LG.

On November 3, 2014, the registrant issued 495,000,000 shares of common stock to Inter-Mountain Capital Corp. (“IMCC”), in partial satisfaction of its obligations under, and IMCC’s election to convert a portion of, the Secured Convertible Promissory Note, dated April 21, 2014, held by IMCC.

On November 4, 2014, the registrant issued 139,963,600 shares of common stock to LG Capital Funding LLC (“LG”), in partial satisfaction of its obligations under, and the holder’s election to convert a portion of, the Primco Management, Inc 8% Convertible Redeemable Note Due February 20, 2015, dated April 1, 2014, held by LG.

On November 5, 2014, the registrant issued 300,000,000 shares of common stock to Firehole River Capital, LLC (“FRC”), in partial satisfaction of its obligations under, and the holder’s election to convert a portion of, the US $ 75,000 Replacement Note – Originally Issued November 6, 2012 in the Amount of $275,000
[to Gorilla Pictures], held by FRC.

The securities issued above were issued pursuant to exemptions from registration requirements relying on Section 4(2) of the Securities Act of 1933 and upon Rule 506 of Regulation D of the Securities Act of 1933 and originally issued with restrictive legend.

 

0 1409

Vaporin Announces Proposed Merger With Vapor Corp.

Enters Into Binding Term Sheet

MIAMI, FL–(Marketwired – Nov 6, 2014) – Vaporin, Inc. (OTCQB: VAPO) (“Vaporin”), a distributor and marketer of vaporizers and e-liquids products, announced today that it has executed a binding term sheet (the “Term Sheet”) to enter into a merger with Vapor Corp. (NASDAQ: VPCO) (“Vapor”), a U.S.-based vaporizer and electronic cigarette company.

As contemplated in the Term Sheet, NASDAQ listed Vapor will be the surviving entity of the merger and Vaporin stockholders would collectively own 45.0% of the issued and outstanding capital stock of the combined company. The transaction is subject to approval by Vaporin and Vapor stockholders, execution of a definitive Merger Agreement, and other customary closing conditions. Any further announcement in connection with the merger will be made when appropriate.

Greg Brauser, Chief Operating Officer of Vaporin, commented: “We are excited to combine Vaporin’s streamlined supply chain, marketing strategies, and innovative product lines with Vapor Corp’s wide distribution capabilities. Leveraging the combined synergies of our two companies will allow us to more rapidly and efficiently capture market share in an expanding market. This merger presents a prime consolidation opportunity for us to continue down the path of aggressive expansion aligned with market demand.”

About Vaporin, Inc.
Vaporin is a distributor and marketer of vaporizers and e-liquids products. The Company focuses on a multi-pronged revenue model comprised of convenience store sales, online retail continuity programs, vending machines, and the acquisition and opening of brick and mortar retail stores. Vaporin’s innovative technology offers the taste of traditional cigarettes without any tar, tobacco, smoke and odor. As an alternative to traditional cigarettes, the unique Vaping Pens product line and Made-In-USA E-Liquid is what makes Vaporin one of the emerging brands in the market. Vaporin is not just an alternative to traditional smoking, but a lifestyle. For more information please visit, www.vaporin.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements including statements relating to the closing of the Merger and capturing market share following the Merger. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Vaporin to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ from those in the forward-looking statements include any issues which may affect the required regulatory approvals issues which may affect the integration of the two companies, and the future operating results of each company. Certain of these factors and risks, as well as other risks and uncertainties are stated in Vaporins’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in Vaporin’s subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Vaporin assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.

Additional Information and Where to Find It.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed merger and upon the execution of a definitive merger agreement, Vapor intends to file a Registration Statement on Form S-4 that will include a joint proxy statement of Vapor and Vaporin and a prospectus of Vapor with the Securities and Exchange Commission (the “Commission”). Both Vapor and Vaporin may file other documents with the Commission regarding the proposed transaction. If a definitive merger agreement is executed by the parties, a definitive joint proxy statement will be mailed to the stockholders of Vapor and Vaporin. Investors and security holders are advised to read the joint proxy statement/prospectus when it becomes available, and any other relevant documents filed with the commission, as well as any amendments or supplements to the documents, because they will contain important information. Investors and security holders may obtain a free copy of the registration statement (when available), including the joint proxy statement/prospectus and other documents containing information about Vapor and Vaporin at the Commission’s website at www.sec.gov. These documents may be accessed and downloaded for free at Vapor’s website at http://www.vapor-corp.com or by directing a request to Harlan Press, Chief Financial Officer, Vapor Corp., at 3001 Griffin Road, Dania Beach, Florida 33312, telephone (888) 766-5351 or at www.vaporin.com or by directing a request to Jim Martin, Chief Financial Officer, Vaporin, Inc. at 4400 Biscayne Boulevard, Miami, Florida 33137, telephone (305) 576-9298.

Participants in the Solicitation.

This communication is not a solicitation of a proxy from any security holder of Vapor or Vaporin. However, Vapor and Vaporin and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Vapor’s and Vaporin’s stockholders in respect of the proposed merger. Information regarding the directors and executive officers of Vapor may be found in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the “Registrant Form 10-K”), which was filed with the Commission on February 26, 2014 and its Current Report on Form 8-K dated April 25, 2014, as filed with the Commission on April 28, 2014, both of which can be obtained free of charge from Vapor’s website. Information regarding the directors and executive officers of Vaporin may be found in its Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the “Vaporin Form 10-K”), which was filed with the Commission on March 27, 2014 and can be obtained free of charge from Vaporin’s website. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Joint Proxy Statement/Prospectus and other relevant materials to be filed with the Commission when they become available.

0 1775

Medical Marijuana, Inc.’s HempMeds Premier Sponsor of National Marijuana Business Conference

HempMeds Showcases Retail-Ready Cannabidiol (CBD) Hemp Oil Products Available in All 50 U.S. States and Territories

SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink:MJNA) is pleased to inform shareholders and the general public that HempMeds(TM) — a corporate portfolio company, exclusive master distributor and contracted marketing company — is the premier sponsor of the 3rd annual Marijuana Business Conference. The conference will be held November 12-14 at the Rio All-Suites Hotel & Casino in Las Vegas, Nevada, and feature more than 125 vendors and host an estimated 2,000 attendees. (Note: Visit the conference website for admission guidelines and pricing.)

“From the NFL addressing concussions and consumers ranging from toddlers to seniors, the nation is waking up to taking action and lifting the prohibition on cannabis,” states Andrew Hard, spokesperson for HempMeds(TM). “This week the nation voted on medical cannabis use and the topic is top of mind with the public. It is perfect timing for HempMeds(TM) to be the premier sponsor of the 3rd annual National Marijuana Business Conference in Las Vegas.”

According to MMJ Business Daily, “The Nevada Department of Health and Human Services on Monday awarded 55 preliminary licenses for dispensaries and more than 300 for permits [for] other types of medical cannabis businesses.”

Hard continues, “HempMeds(TM) will showcase a wide variety of retail-ready cannabis products available for purchase from the show floor. We invite the public and newly approved Nevada cannabis business licensees to attend and learn about these unique non-psychoactive cannabis innovations. HempMeds(TM) provides cannabidiol (CBD) products made from industrial hemp that are already available in all 50 states and more than 40 countries. These natural hemp CBD products allow businesses to get into the ‘green rush’ immediately.”

Marijuana Business Daily’s 3rd annual Marijuana Business Conference & Expo offers attendees:

  • 28 presentations
  • 70 expert speakers
  • Keynote by Ben Cohen of Ben & Jerry’s
  • Networking with 2,000 industry professionals
  • 125 exhibitors featuring the latest products, innovations, and tools to grow a cannabis business
  • Marijuana Business Crash Course
  • Women’s Business Networking Breakfast
  • Investor Pitch Slam featuring live investor presentations

George Jage, President & Publisher of Marijuana Business Daily states, “This is a historic event for the cannabis industry as the largest attended business-to-business marijuana event in North America. The acceleration of the market is staggering with exponential growth potential. As our highest-level event sponsor, HempMeds is a major stand out from our list of 140 exhibiting companies capitalizing on the market’s potential.”

For more information on HempMeds(TM) and their all-natural CBD hemp oil products, visit:www.hempmeds.com. The Company invites the public to get involved in the conversation of the expanding cannabis industry with HempMeds(TM) through the Company’s social media websites on Facebook and Twitter.

About HempMeds

HempMeds(TM) offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds(TM) is a corporate portfolio company of Medical Marijuana, Inc.(OTC Pink:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds(TM) is the communication hub for the Medical Marijuana Inc. portfolio of companies.

About Medical Marijuana Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at:www.MedicalMarijuanaInc.com

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact:
For further information, please contact:
Investor Relations contact:
Perry Coleman
Medical Marijuana, Inc.
P. 443-453-5088
perry@medicalmarijuanainc.com
Public Relations contact:
Andrew Hard
Spokesperson
P. 858-380-5478
andrew.hard@general-hemp.com
Corporate contact:
Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

0 1440

mCig Obtains SEC Approval for VitaCig Inc. Spinoff, 1:1 Dividend, and IPO

BELLEVUE, Wash., Nov. 6, 2014 (GLOBE NEWSWIRE) — mCig(R), Inc. (MCIG) (“mCig”), a technology company that owns, manufactures, and distributes the mCig(R), VitaCig(R), and Vapolution products, is pleased to announce that on November 5, 2014 at 4:00 PM Eastern Standard Time the Securities and Exchange Commission’s (“SEC”) declared effective the VitaCig Inc. amended registration statement (S-1) filed on October 16, 2014 and originally filed on April 21, 2014. The effective notice allows the company to complete its strategic spinoff and pro-rata dividend of VitaCig Inc. to all mCig Inc. shareholders creating two companies pursuing two separate market opportunities.

Following the spinoff, mCig Inc. will continue to pursue the development and growth of its wholly owned brands: mCig(R) and Vapolution. The company will also turn its focus towards additional M&A opportunities within the global legalized cannabis industry. The company will continue to retain 246,000,000 shares of VitaCig Inc. representing nearly 49% of the company’s shares outstanding at the time of the spinoff.

VitaCig Inc. will focus exclusively on the nicotine-free mobile vaporization industry while continuing to innovate its core line of products. In anticipation of this spinoff, the mCig Inc. board initiated a CEO search and has identified several promising candidates. The board plans to formally announce the new position prior to the initiation of trading in VitaCig Inc. shares.

Spinoff, Pro-Rata Dividend Details

With the registration statement effective, mCig Inc. can now declare a 1:1 dividend of VitaCig Inc. shares as disclosed in the registration statement. This will result in one (1) VitaCig Inc. share automatically credited to each shareholder owning one (1) mCig Inc. share (eg: If you own 10,000 mCig Inc. shares you will receive 10,000 VitaCig Inc. shares). The company will be completing the necessary paperwork to declare this dividend over the next few days and will update shareholders once the dividend has been declared.

The company will also be filing a Form 211 with FINRA and OTC Markets, LLC clearing VitaCig Inc. for trading on the OTCQB. This process is anticipated taking 30-60 days from the time of filing. The company plans to complete the paperwork by the end of this week. The company will be submitting two choices for a stock symbol for VitaCig Inc.: “VITA” or “VCIG”. A Press Release will be issued announcing the final symbol selection by FINRA when it is provided.

“We continue to deliver what we promised. While this process was somewhat lengthy at seven months, the result will have profound effects on the future of our company. Let us start with mCig Inc. Our balance sheet will now be strengthened by our ownership of nearly 250,000,000 shares of VitaCig Inc. These shares will allow us to raise capital by selling down shares from time-to-time while incurring zero net dilution to mCig or VitaCig Inc. shareholders. Any sales made by mCig Inc. will be reported to the SEC and made public as transparently as possible if and when they do occur. Our goal is to utilize this capital for growth in the industry we believe in most: Cannabis legalization.”

“As for VitaCig Inc., in less than 4 months it has eclipsed mCig and Vapolution in sales, WDRs and customers. At this stage the brand is exceeding every expectation we had for it and the recent award of trademarks by the US Patent and Trademark Office for the term: “VitaCig(R)” has allowed the company to scale its operations much quicker than when we focused on direct sales. Currently, the company is negotiating several country-specific master-agreements, each of which is potentially worth millions of dollars. In fact, we have identified two potential candidates for CEO that can take the company to the next level both in raising capital and growing sales. Sometimes in life, it is good to know when to let the training wheels come off. We think that moment with VitaCig is now and we are excited to be the largest long-term shareholders of the company,” said Paul Rosenberg, CEO of mCig, Inc.

About mCig, Inc.

mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”) by the world’s 1.2 Billion smokers. The company manufactures and retails the mCig(R) — the world’s most affordable vaporizer priced at only $10. Designed in the USA — the mCig(R) provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 3.0. Through its wholly owned subsidiary, VitaCig, Inc. the company manufactures and retails the VitaCig(R), a $5 nicotine-free eCig that delivers a water-vapor mixed with vitamins and natural flavors. See more at:http://www.mCig.org/, www.Vapolution.com, and www.VitaCig.org

The company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.

mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig(R) one of the leading choices for electronic consumption of plant material. – See more at: http://www.mcig.org/investors/investor-opportunity-subpage/

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.

Contact:
Paul Rosenberg
CEO
1(425)652-5946

0 1373

Supreme Pharmaceuticals Provides Update on Funding, Kincardine Facility, and Leadership Transition Ahead of Investor Meeting

VANCOUVER, BRITISH COLUMBIA–(Marketwired – Nov 6, 2014) – Supreme Pharmaceuticals Inc. (the “Company”) (SPRWF)(SL.V) in conjunction with an “Investor Meet and Greet” to be held today at the Fairmont Pacific Rim in Vancouver BC, provides an update on the Company’s funding status, progress at its facility in Kincardine Ontario, and a leadership transition plan.

According to CEO David Stadnyk, “With yesterday’s private placement closing, we now have funding in place to complete our build-out of the Kincardine facility and take us through the licensing stage and beyond.” Stadnyk also stated that he expects the build-out of the Kincardine facility to be completed by the end of November. “Our team in Kincardine has kept this large and complex project running smoothly and on track,” Stadnyk added. “The skill with which they’ve handled this project confirms my conviction that we have the right team assembled to run operations on the ground.”

Finally, Stadnyk – who has a successful history of funding and staffing new ventures and then transitioning to the role of passive investor and business advisor-announced his plan to move out of his CEO and director roles with the Company.

“I’m proud of what we’ve accomplished at Supreme over the last year, and the contributions that I could make in its early stages,” said Stadnyk. “With our latest raise being finalized and with the management team we’ve assembled in Kincardine and Vancouver, I’m confident that the Company is positioned for an exciting future.”

With Stadnyk’s departure, Brayden R. Sutton, currently Executive Vice President for Supreme in Vancouver, will be expanding his role and taking on additional leadership responsibilities, and George Tsafalas, currently a director at Supreme, will step in as interim President. “We’re grateful for the contributions David has made to Supreme, and for putting the pieces in place for Supreme’s future success. I look forward to helping Supreme continue to grow into a leader in the medical marijuana industry,” said Sutton.

Chris Bechtel, who is currently on Supreme’s Advisory Board, will be appointed to the Board of Directors seat being vacated by Stadnyk. Stadnyk will remain involved in the Company by taking a seat on its Advisory Board.

FORWARD LOOKING INFORMATION

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the pre-licensing inspection by Health Canada, as well as the Company’s corporate strategy. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan following the rejection of the required licenses for the South Okanagan facility by Health Canada. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Contact:
Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
info@supreme.ca
www.supreme.ca

0 1587

Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain

BETHESDA, MD–(Marketwired – Nov 6, 2014) – Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed an IP Licensing and Collaboration Agreement with Kalapa Holding (Spain) for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market.

Kalapa Holding is a leading medical cannabis and hemp grower and distributor in Spain, with a diverse line of cannabinoid based products.

CANNABICS SR medical cannabis products will be available in strict compliance with Spanish laws and regulations to certified patients through the “Asociacion Centro Cannabico de Terapias Naturales,” a registered Spanish entity and affiliate of Kalapa Holding.

CANNABICS SR products will be manufactured and distributed in Spain locally, based on pure extracts produced from select, high quality and organic medical cannabis strains cultivated by the Asociacion Centro Cannabico de Terapias Naturales.

Dr. Zohar Koren, CEO of Cannabics Pharmaceuticals, stated, “We are very excited to launch the collaboration with Kalapa Holding in Spain and thus offer our line of advanced medical cannabis products to European patients for the first time. The substantial synergy that arises through the combination of the extensive operational capabilities and outreach of Kalapa Holding in the Spanish medical cannabis market, combined with our advanced cannabinoid administration technology, as embedded in the CANNABICS SR line of products, ensures that this is a long-term and sustainable partnership.”

Joan De Haro, CEO of Kalapa Holding, added, “We are delighted to initiate our collaboration with Cannabics Pharmaceuticals through the current IP licensing agreement and add the advanced line of CANNABICS SR products to our arsenal of high quality medical cannabis therapies. This achievement is a major milestone in our endeavor to become a leading company in the medical cannabis field in Spain, and it perfectly fits our strategy of connecting patients directly with doctors for exact personal tailoring of advanced and sophisticated medical cannabis therapies.”

About Cannabics Pharmaceuticals, Inc.
Cannabics Pharmaceuticals, Inc. is an emerging drug development company focused on the development and commercialization of advanced drugs, therapies, food supplements and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics’ current flagship product is CANNABICS SR — an IP pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Cannabics’ proprietary SR technology provides 10-12 hours of steady state and beneficial therapeutic effects profile, and thus allows for a convenient oral, once-per-day or twice-per-day dosing regimen of medical cannabis for patients. Cannabics is now preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory pathways, while simultaneously preparing to launch a series of formal clinical studies in order to establish the unique medical benefits of its products for patients suffering from various indications.

For more information, visit www.cannabics.com

About Kalapa Holding, S.L.
Kalapa Holding S.L., headquartered in Barcelona, Spain, is dedicated to the development, production and distribution of nutritional supplements and para-pharmaceutical products based on cannabinoids and additional therapeutic plant extracts. Kalapa Holding controls a network of subsidiaries and affiliated organizations which cover the complete chain of production and distribution, including organic growing facilities, production laboratories, distribution channels and specialized patient care doctor’s offices. By controlling the entire process, high quality products as well as an instant feedback loop from patients for the reported therapeutic effects of the products is achieved. Kalapa Holding collaborates in this process with leading physicians in the main hospitals of Spain. Recently, Kalapa Holding has initiated an incubator for high quality projects in the field of medical cannabis, including R&D projects, production, distribution and digital data processing. In addition, Kalapa Holding consults Cannabis Associations in Spain on the formal development and rigorous control of their therapeutic and medical cannabis programs.

DISCLAIMER:
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 15th, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

Contact:
Cannabics Pharmaceuticals, Inc.
Itamar Borochov
Corporate VP Marketing
877-424-2429
Info@Cannabics.com

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements